

Scientific letter

Differences in the Evolution of Lung Function Before and After Treatment With Antifibrotics in Patients With Interstitial Lung Disease



Diferencias en la evolución de la función pulmonar antes y después del tratamiento con antifibróticos en pacientes con enfermedad pulmonar intersticial difusa

Dear Editor,

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disease of unknown etiology characterized by the scarring of the lung parenchyma,¹ leading to a progressive worsening of dyspnea and lung function, and associated with a poor prognosis.²

Currently, there are two antifibrotic therapies approved for its treatment: pirfenidone and nintedanib.³ However, they are not curative treatments and may be associated with tolerance problems.¹ Pirfenidone demonstrated a relative reduction of patients with forced vital capacity (FVC) decline > 10%, and nintedanib was shown to reduce FVC loss in absolute value. Therefore, IPF is of particular clinical and investigative interest at present.⁴ That is why we have made an observational study with retrospective data collection from patients with interstitial lung disease (ILD) who received treatment with an antifibrotic drug in a tertiary hospital in Madrid. The aims of this study were to investigate the changes in clinical and functional characteristics of patients treated with antifibrotic drugs before and after treatment, to identify the diagnosis that led to antifibrotic treatment, and to describe the frequency of adverse reactions to antifibrotic drugs. This study was approved by the Drug Research Ethics Committee of the Gregorio Marañón General University Hospital, with code 13/2023.

The day of antifibrotic treatment initiation was considered baseline of the study. The functional tests included FVC in absolute value and the diffusing capacity of the lungs for carbon monoxide (DLCO) as a percentage of predicted value. These tests were performed according to the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) guidelines.⁵ Dyspnea was measured using the modified British Research Council scale (mMRC). The presence of concomitant diseases was measured using the Charlson index. The same functional variables and dyspnea were collected for the 12 months prior to baseline, 12 months after baseline, and 24 months after baseline, with a window of one month if these data were available.

Twenty-eight patients were included, 25 (89.3%) was treated with pirfenidone and 3 (10.7%) with nintedanib. Of all patients, 18 (64.3%) were male. The mean age was 66.4 years (SD 8.4) with a median body mass index (BMI) of 25.2 kg/m² (IQR 22.1–28.4). Only one patient (3.6%) had active smoking at baseline. The median Charlson index was 3 (IQR 2–4).

Table 1

Clinical and functional characteristics at month – 12, baseline, month 12, and month 24.

	FVC, mL (SD)	DLCO, % (SD)	Dyspnea, median (IQR)
Month – 12	2656 (663)	59.2 (13.0)	1 (0–1)
Baseline	2428 (735)	52.8 (11.4)	2 (1–3)
Month 12	2709 (945)	51.5 (15.9)	2 (1–2)
Month 24	2567 (835)	51.4 (13.1)	2 (0–2)

FVC: forced vital capacity; DLCO: carbon monoxide diffusing capacity; SD: standard deviation; IQR: interquartile range.

Regarding the diagnosis, all patients (100%) underwent high-resolution computed (HRCT). In this, 8 patients (28.6%) had a radiological pattern of usual interstitial pneumonia (UIP), 9 patients (32.1%) had a pattern of probable UIP, 3 patients (10.7%) had a pattern of fibrotic non-specific interstitial pneumonia (NSIP), and 8 patients (28.6%) did not fit into any of the previous radiological patterns.

To obtain a histological diagnosis, one patient (3.6%) underwent transbronchial biopsy, 6 patients (21.4%) underwent cryobiopsy, and 5 (17.9%) underwent surgical biopsy. In the case of transbronchial biopsy and cryobiopsy, 5 patients (41.7%) had a histological pattern of UIP, 4 patients (33.3%) had a pattern of NSIP, and 3 (25.0%) showed a histological pattern different from the previous ones. In the 4 patients with surgical biopsy, 3 (75.0%) demonstrated the presence of a histological pattern of UIP. In summary, 22 patients (78.6%) had an established diagnosis of idiopathic pulmonary fibrosis (IPF) as an indication for antifibrotic treatment, and this indication in the other 6 patients (21.4%) was determined by the multidisciplinary ILD committee, made up of pulmonologists, rheumatologists, radiologists and pathologists.

The mean FVC mean at baseline was 2428 mL (SD 735), and the mean DLCO was 52.8% (SD 11.4). The comparison of change in FVC, DLCO, and dyspnea between the periods of month – 12 to baseline, baseline to month 12, and month 12 to month 24 are presented in Table 1. A lower loss of FVC and less worsening of dyspnea were observed in the 12 months following the initiation of antifibrotic treatment compared to the 12 months prior, without a documented reduction in DLCO during these periods or during the second year of treatment compared to the first year in any of the three variables. The median follow-up was 40.1 months (IQR 32.9–67.1). During the follow-up, 11 patients (39.3%) died, and 2 (7.1%) underwent lung transplantation. In the deceased patients, the median survival from the initiation of antifibrotic treatment was 37.8 months (IQR 33.4–67.1).

During follow-up, 4 patients (14.3%) experienced gastrointestinal disturbances, 4 patients (14.3%) suffered from photosensitivity, and another 4 (14.3%) had weight loss. These adverse reactions led to temporary suspension of antifibrotic treatment in 5 patients (17.9%) and permanent suspension in 2 (7.1%).

The main finding of our study is that antifibrotic drugs were able to slow down the decline in FVC and worsening of dyspnea during the first year of treatment compared to the previous year, with these parameters stabilizing during the second year of treatment. Results comparable to those found in clinical trials⁶ and also reported by other authors in a multicenter observational study.⁷ However, a reduction in the decline of DLCO was not observed with antifibrotic treatment.

Furthermore, most of the patients who received antifibrotics in our study had a confirmed diagnosis of IPF, but in some cases antifibrotic treatment was prescribed by a multidisciplinary ILD committee even when the patient did not have IPF. In our study, 64.3% of the patients were male. As previously described in the literature, the incidence and prevalence of IPF are higher in males, and the disease progresses more rapidly in this population.^{8,9} Radiology plays an essential role in the diagnosis of IPF, and it can even be diagnostic without the need for anatomopathological confirmation,¹⁰ as was the case in 16 of our patients.

Antifibrotic drugs were safe and well tolerated by the majority of patients, with temporary suspension or withdrawal necessary in 25% of patients, although no serious adverse effects were detected. These data are comparable to the results of the CAPACITY study¹¹ and are also similar to those found in various real-life observational studies, with gastrointestinal disturbances being the most frequent adverse effects.^{6,7,12}

In conclusion, the antifibrotic treatments slowed the decline of FVC and worsening of dyspnea during the first year of treatment compared to the previous year. These treatments were generally well tolerated. These findings encourage the continued use of antifibrotics in indicated cases.

Funding

This study received no external funding.

Authors' contributions

Conceptualization: Katuska Herminia Liendo-Martínez
 Methodology: Zichen Ji
 Software: Zichen Ji
 Validation: Francisco Javier Baratech-Calpena
 Formal analysis: Zichen Ji
 Investigation: Katuska Herminia Liendo-Martínez and Francisco Javier Baratech-Calpena
 Resources: Fernando Pedraza-Serrano and Francisco José Caballero-Segura
 Data curation: Katuska Herminia Liendo-Martínez
 Writing—original draft preparation: Katuska Herminia Liendo-Martínez and Francisco Javier Baratech-Calpena
 Writing—review and editing: Javier de Miguel-Díez
 Visualization: Javier de Miguel-Díez

Supervision: Javier de Miguel-Díez
 Project administration: Javier de Miguel-Díez
 Funding acquisition: N/A

Conflicts of interest

The authors declare that they have no conflict of interest directly or indirectly related to the contents of this manuscript.

References

1. Spagnolo P, Kropski JA, Jones MG, Lee JS, Rossi G, Karamitsakos T, et al. Idiopathic pulmonary fibrosis: disease mechanisms and drug development. *Pharmacol Ther.* 2021;222:107798.
2. Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. *Am J Respir Crit Care Med.* 2022;205:e18–47.
3. Glass DS, Grossfeld D, Renna HA, Agarwala P, Spiegler P, DeLeon J, et al. Idiopathic pulmonary fibrosis: current and future treatment. *Clin Respir J.* 2022;16:84–96.
4. Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. *N Engl J Med.* 2018;378:1811–23.
5. García-Río F, Calle M, Burgos F, Casan P, Del Campo F, Galdiz JB, et al. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). Spirometry. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). *Arch Bronconeumol.* 2013;49:388–401.
6. Poletti V, Vancheri C, Albera C, Harari S, Pesci A, Metella RR, et al. Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study. *Respir Res.* 2021;22:66.
7. Avdeev S, Ilkovich M, Terpigorev S, Moiseev S, Tyurin I. Effects of pirfenidone on idiopathic pulmonary fibrosis progression and safety: results of multicenter prospective observational study. *Life (Basel).* 2023;13:483.
8. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2006;174:810–6.
9. Han MK, Murray S, Fell CD, Flaherty KR, Toews GB, Myers J, et al. Sex differences in physiological progression of idiopathic pulmonary fibrosis. *Eur Respir J.* 2008;31:1183–8.
10. Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. *Lancet Respir Med.* 2018;6:138–53.
11. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. *Lancet.* 2011;377:1760–9.
12. Fang C, Huang H, Guo J, Ferienc M, Xu Z. Real-world experiences: efficacy and tolerability of pirfenidone in clinical practice. *PLOS ONE.* 2020;15:e0228390.

Katuska Herminia Liendo-Martínez^{a,b},
 Francisco Javier Baratech-Calpena^b, Zichen Ji^{a,*},
 Fernando Pedraza-Serrano^a, Francisco José Caballero-Segura^{a,b},
 Javier de Miguel-Díez^{a,b}

^a Respiratory Department, Gregorio Marañón General University Hospital, 28007 Madrid, Spain

^b Faculty of Medicine, Complutense University of Madrid, 28040 Madrid, Spain

* Corresponding author.

E-mail address: jizich72@gmail.com (Z. Ji).